A citation-based method for searching scientific literature

Diego Kauffmann-Guerrero, Kathrin Kahnert, Rudolf M Huber. Drugs 2021
Times Cited: 7







List of co-cited articles
22 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
Jessica J Lin, Viola W Zhu, Satoshi Yoda, Beow Y Yeap, Alexa B Schrock, Ibiayi Dagogo-Jack, Nicholas A Jessop, Ginger Y Jiang, Long P Le, Kyle Gowen,[...]. J Clin Oncol 2018
197
42

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
D Ross Camidge, Rafal Dziadziuszko, Solange Peters, Tony Mok, Johannes Noe, Malgorzata Nowicka, Shirish M Gadgeel, Parneet Cheema, Nick Pavlakis, Filippo de Marinis,[...]. J Thorac Oncol 2019
218
42

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli,[...]. N Engl J Med 2020
292
28

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell,[...]. N Engl J Med 2017
28

Optimal management of ALK-positive NSCLC progressing on crizotinib.
Giulio Metro, Marco Tazza, Roberta Matocci, Rita Chiari, Lucio Crinò. Lung Cancer 2017
27
28

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Alice T Shaw, Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Chia-Chi Lin, Ross A Soo, Gregory J Riely, Sai-Hong Ignatius Ou, Jill S Clancy, Sherry Li,[...]. J Clin Oncol 2019
179
28

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Eunice L Kwak, Yung-Jue Bang, D Ross Camidge, Alice T Shaw, Benjamin Solomon, Robert G Maki, Sai-Hong I Ou, Bruce J Dezube, Pasi A Jänne, Daniel B Costa,[...]. N Engl J Med 2010
28

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Toyoaki Hida, Hiroshi Nokihara, Masashi Kondo, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Hiroshige Yoshioka, Fumio Imamura,[...]. Lancet 2017
550
28

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Alice T Shaw, Tae Min Kim, Lucio Crinò, Cesare Gridelli, Katsuyuki Kiura, Geoffrey Liu, Silvia Novello, Alessandra Bearz, Oliver Gautschi, Tony Mok,[...]. Lancet Oncol 2017
329
28

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Enriqueta Felip, Ross A Soo, D Ross Camidge, Rita Chiari, Alessandra Bearz, Chia-Chi Lin, Shirish M Gadgeel,[...]. Lancet Oncol 2018
390
28

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression.
Azusa Tanimoto, Shingo Matsumoto, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Akihiro Nishiyama, Kiyotaka Yoh, Takaya Ikeda, Naoki Furuya, Kazumi Nishino,[...]. Clin Cancer Res 2021
12
28

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA.
Steffen Dietz, Petros Christopoulos, Zhao Yuan, Arlou Kristina Angeles, Lisa Gu, Anna-Lena Volckmar, Simon J Ogrodnik, Florian Janke, Chiara Dalle Fratte, Tomasz Zemojtel,[...]. EBioMedicine 2020
24
28

Identification of a highly lethal V3+ TP53+ subset in ALK+ lung adenocarcinoma.
P Christopoulos, M Kirchner, F Bozorgmehr, V Endris, M Elsayed, J Budczies, J Ristau, R Penzel, F J Herth, C P Heussel,[...]. Int J Cancer 2019
50
28


Therapeutic Sequencing in ALK+ NSCLC.
Mei Elsayed, Petros Christopoulos. Pharmaceuticals (Basel) 2021
20
28

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
633
28

Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.
Mohammad Jahanzeb, Huamao M Lin, Xiaoyun Pan, Yu Yin, Pia Baumann, Corey J Langer. Clin Lung Cancer 2021
21
28

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.
S Novello, J Mazières, I-J Oh, J de Castro, M R Migliorino, Å Helland, R Dziadziuszko, F Griesinger, A Kotb, A Zeaiter,[...]. Ann Oncol 2018
166
28

EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancer.
Petros Christopoulos, Volker Endris, Farastuk Bozorgmehr, Mei Elsayed, Martina Kirchner, Jonas Ristau, Ivo Buchhalter, Roland Penzel, Felix J Herth, Claus P Heussel,[...]. Int J Cancer 2018
76
28

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020
305
28

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Masahiro Tsuboi, Jie He, Thomas John, Christian Grohe, Margarita Majem, Jonathan W Goldman, Konstantin Laktionov, Sang-We Kim, Terufumi Kato,[...]. N Engl J Med 2020
524
28

Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Weihua Li, Lei Guo, Yutao Liu, Lin Dong, Lin Yang, Li Chen, Kaihua Liu, Yang Shao, Jianming Ying. J Thorac Oncol 2021
34
28

Novel ALK fusion partners in lung cancer.
Aglaya G Iyevleva, Grigory A Raskin, Vladislav I Tiurin, Anna P Sokolenko, Natalia V Mitiushkina, Svetlana N Aleksakhina, Aigul R Garifullina, Tatiana N Strelkova, Valery O Merkulov, Alexandr O Ivantsov,[...]. Cancer Lett 2015
58
14

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.
Nir Peled, Roni Gillis, Saadettin Kilickap, Patrizia Froesch, Sergei Orlov, Elena Filippova, Umut Demirci, Petros Christopoulos, Irfan Cicin, Fatma Bugdayci Basal,[...]. Lung Cancer 2020
11
14

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.
Michaël Duruisseaux, Benjamin Besse, Jacques Cadranel, Maurice Pérol, Bertrand Mennecier, Laurence Bigay-Game, Renaud Descourt, Eric Dansin, Clarisse Audigier-Valette, Lionel Moreau,[...]. Oncotarget 2017
102
14

ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer.
Gina Rosas, Rossana Ruiz, Jhajaira M Araujo, Joseph A Pinto, Luis Mas. Crit Rev Oncol Hematol 2019
26
14

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Alice T Shaw, Leena Gandhi, Shirish Gadgeel, Gregory J Riely, Jeremy Cetnar, Howard West, D Ross Camidge, Mark A Socinski, Alberto Chiappori, Tarek Mekhail,[...]. Lancet Oncol 2016
471
14

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
D Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji-Youn Han, Jong-Seok Lee, Maximilian J Hochmair, Jacky Yu-Chung Li, Gee-Chen Chang, Ki Hyeong Lee,[...]. N Engl J Med 2018
460
14

An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.
Viola W Zhu, Yen-Ting Lin, Dong-Wan Kim, Herbert H Loong, Misako Nagasaka, Hao To, Yvonne Li-En Ang, Chan-Young Ock, Nishan Tchekmedyian, Sai-Hong Ignatius Ou,[...]. J Thorac Oncol 2020
28
14

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis.
Maximilian J Hochmair, Hannah Fabikan, Oliver Illini, Christoph Weinlinger, Ulrike Setinek, Dagmar Krenbek, Helmut Prosch, Markus Rauter, Michael Schumacher, Ewald Wöll,[...]. Pharmaceuticals (Basel) 2020
9
14

Pharmacogenomics.
Dan M Roden, Howard L McLeod, Mary V Relling, Marc S Williams, George A Mensah, Josh F Peterson, Sara L Van Driest. Lancet 2019
163
14

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
Helen Y Zou, Qiuhua Li, Lars D Engstrom, Melissa West, Vicky Appleman, Katy A Wong, Michele McTigue, Ya-Li Deng, Wei Liu, Alexei Brooun,[...]. Proc Natl Acad Sci U S A 2015
170
14

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy,[...]. Lancet Oncol 2019
152
14

Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody.
Hiroshi Matsuoka, Takahiro Hayashi, Karen Takigami, Kazuyoshi Imaizumi, Ryoichi Shiroki, Naoki Ohmiya, Kazumitsu Sugiura, Kenji Kawada, Akira Sawaki, Koutaro Maeda,[...]. BMC Cancer 2020
32
14

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James,[...]. Lancet Oncol 2017
394
14

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer.
Timothy A Yap, Aislinn Macklin-Doherty, Sanjay Popat. Eur J Cancer 2017
29
14

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
Dong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, Karen L Reckamp, Karin Holmskov Hansen, Sang-We Kim, Rudolf M Huber, Howard L West, Harry J M Groen, Maximilian J Hochmair,[...]. J Clin Oncol 2017
373
14

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.
Sun Min Lim, Hye Ryun Kim, Jong-Seok Lee, Ki Hyeong Lee, Yun-Gyoo Lee, Young Joo Min, Eun Kyung Cho, Sung Sook Lee, Bong-Seog Kim, Moon Young Choi,[...]. J Clin Oncol 2017
191
14

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
14

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf,[...]. Lancet Oncol 2020
196
14

RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
Claudia Vollbrecht, Dido Lenze, Michael Hummel, Annika Lehmann, Markus Moebs, Nikolaj Frost, Philipp Jurmeister, Leonille Schweizer, Udo Kellner, Manfred Dietel,[...]. BMC Cancer 2018
16
14

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.
E Thunnissen, B I Lissenberg-Witte, M M van den Heuvel, K Monkhorst, B G Skov, J B Sørensen, A Mellemgaard, A M C Dingemans, E J M Speel, A J de Langen,[...]. Lung Cancer 2019
8
14



Sequential blinded treatment decisions in ALK-positive non-small cell lung cancers in the era of precision medicine.
J Remon, F Tabbò, B Jimenez, A Collazo, J de Castro, S Novello. Clin Transl Oncol 2020
5
20

HER2 regulates cancer stem-like cell phenotype in ALK translocated NSCLC.
Tiia Honkanen, Emmi Wilenius, Peppi Koivunen, Jussi P Koivunen. Int J Oncol 2017
4
25


Scientific Advances in Lung Cancer 2015.
Anne S Tsao, Giorgio V Scagliotti, Paul A Bunn, David P Carbone, Graham W Warren, Chunxue Bai, Harry J de Koning, A Uraujh Yousaf-Khan, Annette McWilliams, Ming Sound Tsao,[...]. J Thorac Oncol 2016
173
14

Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
Kiyoko Koyama, Naoko Katsurada, Naoe Jimbo, Motoko Tachihara, Daisuke Tamura, Kyosuke Nakata, Tatsuya Nagano, Masatsugu Yamamoto, Hiroshi Kamiryo, Kazuyuki Kobayashi,[...]. Pathol Int 2019
7
14



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.